An interventional study of 595 nm Pulsed dye laser (Candela V-beam perfecta) in Psoriasis Vulgaris, sponsored by Nick van der Beek. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Nick van der Beek · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Psoriasis with a site in Netherlands — 5 open to participants now, 8 under way, 1 of them phase 3. Psoriasis · Netherlands.
Among the 65 studies in Psoriasis with a site in Netherlands, this one is the 49th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 with no phase, and was the 58th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 65 studies in Psoriasis with a site in Netherlands are open now. Recruiting first, the newest first:
Zealand Pharma · Sites in Netherlands
Ages 18–60
Leiden University Medical Center · Sites in Netherlands
Ages 18+ · Healthy volunteers
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Medisch Spectrum Twente · Sites in Netherlands
Ages 16+
Nick van der Beek · Sites in Netherlands
Ages 18–64
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 26 · Phase 4 11
First in 2001; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 276 across the 50 interventional studies, 719 across the 15 observational. Of the 55 that completed or were terminated, 30 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 65 have an industry lead sponsor. The 10 most frequent:
Nick van der Beek is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Nick van der Beek has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
1 of the studies in Psoriasis with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07733089Zealand PharmaA Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 65 studies in Psoriasis with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The researchers investigate the effect of a treatment with selective photothermolysis using a 595 nm pulsed dye laser on the blood vessel density and the nerve fibre density of a psoriatic lesion. By comparing tissue samples collected before and after two treatments, the researchers determine the relative effect of laser therapy on the (hyper)innervation of psoriatic skin.
Vascular laser therapy for psoriasis seems to achieve a remarkably long treatment-free duration of remission. But why would sub-second heating of the blood vessels of the skin result in a year-long resolution of an infamously stubborn condition?
Unraveling the mechanism of action of laser therapy would not only allow for the improvement of existing laser therapy protocols but also, could open the door to a whole new range of interventions offering quasi-permanent solutions for patients. There is a high need for such enduring therapies: Psoriasis is both, a common and a costly skin condition. It affects between 1% and 9% of the population and has a very severe impact on the quality of life of the patient. It's chronic character implies lifelong treatment, and the associated risks and effort
This project aims to assess the effect of laser therapy on the blood vessels and (peripheral) innervation of psoriasis plaques. The primary objective is to quantify the regression and recovery of nerves compared to blood vessels. The researchers hypothesize that the recovery of nerves after Selective Photo Thermolysis (SPT) is decreased compared to the recovery of blood vessels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study if:
595 nm Pulsed dye laser (PDL) therapy for psoriasis
Device: 595 nm Pulsed dye laser (Candela V-beam perfecta)
595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
Recovery ration
Relative change in the ratio of the linear nerve density and linear blood vessel density.
Time frame: 6 months.
Recovery ratio vs lymphocyte infiltration
Correlation between change in the ratio of the linear nerve density and linear blood vessel density versus change in number of infiltrating lymphocytes
Time frame: 6 months
Clinical improvement
Change in severity determined using a visual-analogue scale.
Time frame: 6 months
Plan to share: No — The data acquired during the investigation will be made available upon request.
Ran from Dec 2022 to primary completion in Oct 2024, 22 months.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 22 months is close to that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nick van der Beek